Literature DB >> 7740616

Spontaneous resolution of transfusion-associated graft-versus-host disease.

S Mori1, H Matsushita, K Ozaki, A Ishida, M Tokuhira, H Nakajima, M Kizaki, H Sugiura, A Kikuchi, M Handa.   

Abstract

BACKGROUND: Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood transfusion that is characterized by high fever, a scaly maculopapular erythematous rash, diarrhea, hepatocellular damage with marked elevation of liver function test values, and pancytopenia. It can occur in immunocompetent as well as immunocompromised recipients. The existence of atypical TA-GVHD that resolves spontaneously and does not exhibit all of the manifestations has been suggested, but there has been to date no documented diagnosis of GVHD supported by evidence of engraftment. CASE REPORT: A female patient presented and was diagnosed with acute myelogenous leukemia (AML:M4), and, after unsuccessful combination chemotherapy, she received a transfusion and developed manifestation of TA-GVHD as well as evidence of chimerism. TA-GVHD was proved by demonstrating Y chromosome-specific genes in the skin by polymerase chain reaction. The manifestations of clinical GVHD abated within 4 months.
CONCLUSION: Polymerase chain reaction analysis of Y chromosomes in specimens from female patients is useful in the diagnosis of suspected cases of spontaneously resolving TA-GVHD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740616     DOI: 10.1046/j.1537-2995.1995.35595259155.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  Transfusion-Associated Graft-Versus-Host Disease with a Non-fatal Course.

Authors:  Suruchi Gupta; Tushar Sehgal; Man Updesh Singh Sachdeva; Shano Naseem; Reena Das; Ritambhra Nada
Journal:  Indian J Hematol Blood Transfus       Date:  2016-04-12       Impact factor: 0.900

2.  Transfusion associated GVHD.

Authors:  Inderpreet Sohi; Sunitha Jacob
Journal:  Indian J Pediatr       Date:  2005-06       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.